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5′-adenosine monophosphate-activated protein kinase (AMPK) is considered central in reg-
ulation of energy status and substrate utilization within cells. In heart failure the energetic
state is compromised and substrate metabolism is altered. We hypothesized that this
could be linked to changes in AMPK activity and we therefore investigated mitochondr-
ial oxidative phosphorylation capacity from the oxidation of long- and medium-chain fatty
acids (LCFA andMCFA) in cardiomyocytes from young and old mice expressing a dominant
negative AMPKα2 (AMPKα2-KD) construct and their wildtype (WT) littermates.We found a
35–45% (P < 0.05) lower mitochondrial capacity for oxidizing MCFA in AMPKα2-KD of both
age-groups, compared toWT.This coincided with marked decreases in protein expression
(19/29%, P < 0.05) and activity (14/21%, P < 0.05) of 3-hydroxyacyl-CoA-dehydrogenase
(HAD), in young and old AMPKα2-KD mice, respectively, compared toWT. Maximal LCFA
oxidation capacity was similar in AMPKα2-KD and WT mice independently of age imply-
ing that LCFA-transport into the mitochondria was unaffected by loss of AMPK activity or
progressing age. Expression of regulatory proteins of glycolysis and glycogen breakdown
showed equivocal effects of age and genotype. These results illustrate that AMPK is nec-
essary for normal mitochondrial function in the heart and that decreased AMPK activity
may lead to an altered energetic state as a consequence of reduced capacity to oxidize
MCFA.We did not identify any clear aging effects on mitochondrial function.
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INTRODUCTION
The energy supply of the cardiomyocytes in thepumpingheart is of
vital importance for the sustained delivery of substrates to all other
cells in the organism. The hearts own substrate availability must
therefore be guaranteed at all times and a tight regulation must
exist in order to balance energy mobilization and expenditure. 5′-
Adenosine monophosphate-activated protein kinase (AMPK) is
considered a key enzyme in this respect, and is classically described
as a cellular energy sensor (Hardie et al., 2006). Energetic stress
leading to a high AMP:ATP ratio is a potent stimulator of AMPK
activity resulting in increased myocellular uptake of glucose and
fatty acids (FA) and increased glycolysis (Dolinsky andDyck, 2006;
Viollet et al., 2009).
5′-Adenosinemonophosphate-activated protein kinase has pri-
marily been shown to participate in short-term energy regulation
of cardiac metabolism and gene expression in healthy organ-
isms whereas less is known about its actions in cellular adap-
tive responses to disease (Dolinsky and Dyck, 2006; Dyck and
Lopaschuk, 2006; Viollet et al., 2009). Transgenic mice are use-
ful tools for elucidating this area and so far it has been shown
that loss of function of various AMPK subunits result in different
cardiac pathologies (Dolinsky and Dyck, 2006). Mutations in
the PRKAG2 gene encoding the AMPK-γ2 regulatory subunit,
leads to altered AMPK activity and a cardiac phenotype resem-
bling Wolff–Parkinson–White syndrome, with increased glycogen
deposition in the myocardium and potential to induce ventric-
ular pre-excitation (Arad et al., 2002; Gollob and Roberts, 2002;
Sidhu et al., 2005). Moreover, a loss of function of the catalytic
AMPKα2 subunit is associated with modest left ventricular con-
tractile dysfunction (Russell III et al., 2004; Turdi et al., 2010)
and increased susceptibility to ischemic events (Xing et al., 2003;
Gundewar et al., 2009; Kim et al., 2011) thereby underlining its
role in maintaining cardiac function. We hypothesized that the
common effector mechanism of AMPK in these pathologies could
be disturbances in mitochondrial substrate utilization and there-
fore aimed at characterizing mitochondrial substrate utilization
in a mouse model over-expressing a dominant negative isoform
of the catalytic AMPKα2 subunit as described earlier (Mu et al.,
2003). We hypothesized that functioning AMPK is necessary for
the orchestration of substrate utilization in the heart andwe aimed
speciﬁcally at investigating mechanisms that could inﬂuence the
capacity for mitochondrial FA oxidation since this has been shown
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to be severely affected by various cardiac pathological conditions
(Neubauer, 2007). The incidence of cardiac disease is much higher
in an aged population and since studies have shown depressed
AMPK activity with aging (Ma et al., 2010) we found it relevant to
study cardiac metabolic phenotype in both young and old mice.
MATERIALS AND METHODS
ANIMALS
Protocols were approved by the Danish Animal Experimental
Inspectorate and complied with the European Convention for
the Protection of Vertebrate Animals used for Experimental and
Other Scientiﬁc Purposes (Council of Europe no. 123, Stras-
bourg, France, 1985). Male, muscle-speciﬁc AMPKα2 kinase dead
(AMPKα2-KD) mice (Mu et al., 2003) and wildtype (WT) male
littermates on a C57BL/6J background were studied. The mice
within each group represented two age-groups: young (Y) (19–
22weeks) and old (O) animals (76–91weeks). This rendered four
groups: WT/Y (n = 12), WT/O (n = 8), AMPKα2-KD/Y (n = 14),
and AMPKα2-KD/O (n = 8). Body weight (BW) was lower in
young than in old mice (33.1± 0.4 vs. 35.8± 0.5 g, P < 0.05) with
no effect of genotype. All mice were housed in a 10:14-h light-dark
cycle and fed standard laboratory chow and water ad libitum. The
heart was excised after anesthesia with intraperitoneal pentobar-
bital/lidocaine injection. The heart was transferred to an ice cold
buffer solution (BIOPS, see below), the atria andmajor vesselswere
quickly removed, and the ventricles were divided in two portions;
one for high resolution respirometry (from apex of left ventricle)
and one for clamp freezing in liquid nitrogen and storage at−80˚C
for later biochemical analyses.
HIGH RESOLUTION RESPIROMETRY
Cardiac tissue from the apex of the left ventricle was prepared for
measurements of respiratory ﬂux rates by mechanical dissection
with sharp forceps in relaxing buffer (BIOPS) on ice. The buffer
contained 2.77mM CaK2EGTA, 7.23mM K2EGTA, 20mM imi-
dazole, 20mM taurine, 6.56mM MgCl2, 5.77mM ATP, 15mM
phosphocreatine, 0.5mM dithiothreitol, and 50mM K-MES at
pH 7.1. Myocardial ﬁbers were permeabilized by gentle agita-
tion for 30min at 0˚C in BIOPS supplemented with 50μg/ml
saponin and then washed in ice cold respiration medium (Mir05)
2× 10min during gentle agitation. Mir05 consisted of 110mM
sucrose, 60mM K-lactobionate, 0.5mM EGTA, 1 g/l BSA essen-
tially FA free, 3mM MgCl2, 20mM taurine, 10mM KH2PO4,
20mM K-HEPES at pH 7.1. The O2 solubility of this medium
was taken as 10.5μM/kPa.
Respiration was measured at 37˚C (Oroboros, Oxygraph; Inns-
bruck, Austria). Data acquisition and analyses were performed
using DatLab software (Oroboros). The absolute respiratory rates
(oxygen ﬂuxes) were expressed per milligram of wet weight (ww)
per second. Two protocols were performed in parallel, diverting
with respect to the type of FA added. In protocol A, a medium-
chain fatty acid (MCFA) was added whereas a long chain fatty
acid (LCFA) was added in protocol B. Protocol A: malate (M)
2mM,octanoylcarnitine (Oct.car) 0.5mM,andADP5mM.Proto-
col B:malate 2mM,palmitoylcarnitine (Pal.car) 125μM,andADP
5mM.The optimal concentration of octanoylcarnitine and palmi-
toylcarnitine was chosen on basis of substrate titrations in a pilot
study (data not shown) providing maximal state 3 respiration.
Cytochrome C (10mM) was added in four randomly selected sep-
arate protocols to test for outer membrane integrity. This did
not elicit any additive oxygen consumption during maximally
stimulated respiration, verifying the intactness of the outer mito-
chondrialmembranes in the permeabilizedmuscle ﬁbers (data not
shown).
PREPARATION OF TISSUE FOR WESTERN BLOTTING AND PCR
ANALYSIS
The frozen hearts were thoroughly pulverized using a steel-morter
shaped to accommodate a Cryotube™and a steel piston shaped
to ﬁt the inside of the tube. All utensils were kept on dry-ice
in a −20˚C environment. Samples were stored at −80˚C after
processing.
RT-PCR QUANTIFICATION OF GENOMIC DNA AND MITOCHONDRIAL
DNA
Total DNA was precipitated from 10mg of the pulverized mouse
heart homogenized in DNAzol (Molecular Research Center,
Cincinnati, OH, USA). The DNA was dissolved in 200μl Tris–
EDTA pH 8. Five microliters of a 25 times DNA dilution was used
for PCR ampliﬁcation with QuantiTect SYBR Green PCR Mas-
ter Mix (Qiagen, Hilden, Germany) containing 2.5 pmol of each
primer in a total volume of 25μl. Levels of mitochondrial DNA
(mtDNA) and genomic DNA (gDNA) were determined by real-
time PCR using a MX3005P QPCR machine (Stratagene, La Jolla,
CA, USA) as previously described (Rabol et al., 2009) was quan-
tiﬁed using primers for the cytochrome C oxidase Vb (COX-Vb)
gene andmtDNAwas quantiﬁed using primers for the cytochrome
C oxidase I (COX-I) gene. Primer sequences are listed in Table 1.
QUANTIFICATION OF mRNA LEVELS BY REAL-TIME PCR
Total RNA was isolated from 10mg of pulverized heart tissue by
phenol extraction using TRIzol (Invitrogen, San Diego, CA, USA)
according to manufacturer’s instructions. One microgram RNA
was used for mRNA conversion into 20μl cDNA, using oligo-dt
primers and OmniScript reverse transcriptase (Qiagen, Hilden,
Germany). For each target mRNA, 0.25μl cDNA was mixed with
QuantiTect SYBR Green PCR Kit (Qiagen) and 2.5 pmol of each
speciﬁc primer (Table 1) in a total volume of 25μl. The PCR
ampliﬁcation was monitored in real-time using the MX3000P
QPCR machine (Stratagene, La Jolla, CA, USA) and levels of
mRNAs were measured relative to the individual level of β-actin
mRNA (2−ΔCt method; Schmittgen and Livak, 2008). Finally the
level of speciﬁc mRNAs from each group was normalized to the
mean of WT/Y.
The primers had less than 10% variation in PCR efﬁciency
(Table 1; Schmittgen and Livak, 2008) and β-actin mRNA was val-
idated as internal reference, via a two-wayANOVA showing similar
mRNA expression of β-actin in all groups.
WESTERN BLOT ANALYSES
Approximately 15mg of frozen pulverized heart biopsies were
homogenized in ice cold buffer [25mM Tris pH 6.8, 5mM
EDTA, 20mM β-glycerophosphate (Sigma), 10mM pyrophos-
phate (Sigma), 2mM Na Ortovanadate (Sigma), 2.5mM PMSF
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Table 1 | Primer sequences used in RT-PCR quantification of mRNA and DNA.
Gene of interest Forward primer (FW) Reverse primer (RV) PCR efficiency
mRNA β-actin 5′-CTGAACCCTAAGGCCAACCG-3′ 5′-CAGCCTGGATGGCTACGTACA-3′ 1.97
CPT1A 5′-GAACTCAAACCTATTCGTCTTCTG-3′ 5′-GTGTTGGATGGTGTCTGTCTC-3′ 1.91
CPT1B 5′-GGTCCCATAAGAAACAAGACCTC-3′ 5′-AGACGATGTAAAGGGCAGAAGAGG-3′ 1.94
CPT2 5′-CCAAGCACAGTGTGGGCGAGC-3′ 5′-AGGGTGACCCCTCTGGCTGCT-3′ 1.95
gDNA COX-Vb 5′-AGTGCAGTGGCAGGCGTT-3′ 5′-CCTTGGTGCCTGAAGCTGCCT-3′
mtDNA COX-I 5′-GTGCTAGCCGCAGGCATTAC-3′ 5′-CTGGGTGCCCAAAGAATCAG-3′
gDNA, genomic DNA; mtDNA, mitochondrial DNA; COX-Vb, cytochrome C oxidase Vb; COX-I, cytochrome C oxidase I; CPT1A, Carnitine palmitoyl transferase 1A-
isoform; CPT1B, Carnitine palmitoyl transferase 1B-isoform; CPT2, Carnitine palmitoyl transferase 2.
PCR efﬁciency: fold increase per PCR cycle.
and Mini Complete Protease inhibitor tablet according to the
manufactures recommendation (Roche)] and added SDS to a ﬁnal
concentration of 3%. From each sample 3–40μg of total pro-
tein were separated by SDS-PAGE and transferred to polyvinyli-
dene diﬂuoride (PVDF) membranes. Membranes were probed
with antibodies against glycogen-phosphorylase (GP), (AS09 455,
Agrisera), 3-hydroxyacyl-CoA-dehydrogenase (HAD), (ab54477,
Abcam), hexokinase II (HKII), (#2867, Cell Signaling Technol-
ogy), malonyl-CoA-decarboxylase (MCD), (15265-1-AP, Protein
Tech Group), pyruvate kinase – muscle isoform (PK), (#3106, Cell
Signaling Technology), phosphorylated acetyl-CoA-carboxylase
(ACCphos), (#07-303,Millipore),phosphorylatedAMP-dependent
kinase (AMPKphos), (#2531Cell Signaling Technology), or anti-
body against the AMPK-α2 subunit which was kindly provided
by Prof. D. G. Hardie (University of Dundee) followed by incuba-
tion with HRP-labeled secondary antibody (Dako,Denmark). The
antigen-antibody complexes were visualized by ECL using a CCD
system (LAS-4000 Luminescent Image Analyzer, GE Healthcare)
and a Kodak Image Station (2000MM,Kodak). Quantiﬁcationwas
performed using “Image Quant” analysis software (GE Health-
care) and Kodak ID 3.6 software. Western blotting analyses were
performed in two different laboratories. As a result the gels were
loaded differently as illustrated by the representative blots shown
in Figure 5. Not all blots allowed for direct comparisons between
the groups and therefore all protein expression data are reported
relative to the same control group,WT/Y, which were included on
all gels. All gels were run in duplicates.
ENZYME ACTIVITIES
Maximal CS andHAD activity wasmeasured in a reaction coupled
to conversionof NAD+ toNADH.NADHproductionwas assessed
spectrophotometrically, by determination of NADH changes at
340 nm at 37˚C, pH 7.0, in myocardial lysates (1μg/μl protein),
using an automatic analyzer (Hitachi automatic analyzer 912;
Boehringer Mannheim,Germany). CS activity was measured with
acetyl-CoA and oxaloacetate as substrate and HAD measured with
acetoacetyl-CoA as substrate.
STATISTICS
Anthropometric data were compared using an unpaired Student’s
t -test. Protein expression datawas assessed in a groupwisemanner
by a one-way ANOVA. This allowed us to compare the groups of
interest (WT/O/, AMPKα2-KD/Y, and AMPKα2-KD/O) directly
to WT/Y but did not allow for detection of interaction effects of
either age or genotype as isolated factors.Data on enzyme activities
were compared by a two-way ANOVA. In oxygraphic measure-
ments repeated measure two-way ANOVA was used. P values
less than 0.05 were considered signiﬁcant. If the criterion of nor-
mal distribution and equal variance was not met, values were log
transformed and recalculated. Data are expressed as means± SE.
RESULTS
DECREASED AMPK-α2 ACTIVITY IN BOTH YOUNG AND OLD
AMPKα2-KD MICE
The genotypes were conﬁrmed by western blots of the α-p172
AMPK (AMPKphos). The transgenic AMPK-α2 carried a myc tag
and migrated slightly slower in the gels (Figure 5). The expression
of AMPKphos was expectedly higher in theAMPKα2-KD genotype
(data not shown) in line with previous ﬁndings (Mu et al., 2003).
The decreased functional activity of AMPK in KD mice was con-
ﬁrmed by a 74.0± 0.0 and 71.0± 0.1% reduction in the protein
expression level of ACCphos in young and old AMPKα2-KD mice
respectively (Figure 5). ACC is a well known downstream target
of AMPK and its use as a marker of AMPK activity has previously
been validated (Dyck and Lopaschuk, 2006).
DECREASE IN MITOCHONDRIAL MCFA RESPIRATION IN AMPKα2-KD
MICE – IRRESPECTIVE OF AGE
In protocol A, baseline respiration revealed no signiﬁcant dif-
ferences between groups (P > 0.05, data not shown). With the
addition of saturating amounts of ADP and MCFA (Oct.car), res-
piration increased markedly and there was a clear genotype effect,
of reduced oxidative capacity in both young and oldAMPKα2-KD
compared to WT littermates (P < 0.05, Figure 1).
Protocol B revealed no differences in LCFA sustained respira-
tionbetween genotypes or age-groups. Thus, respirationwithADP
and LCFA (Pal.car) did not differ between the groups (P > 0.05,
Figure 1).
NO CHANGE IN MITOCHONDRIAL CONTENT WITH AGE AND/OR
GENOTYPE
There was no difference in mtDNA content (copy no · mg ww−1)
between any groups and the CS activity did also not differ sig-
niﬁcantly between the groups. (P > 0.05, Figure 2) Thus, we
found maintained mitochondrial density irrespective of age and
genotype.
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FIGURE 1 | Mitochondrial respiratory capacity in heart muscle samples
from wild type mice (WT) and dominant negative AMPKα2 (AMPK KD)
mice.Young (Y: 19–22weeks) and old (O: 76–91weeks) mice were studied
in both groups. State 3 respiration was measured with two different
substrate protocols. Malate, ADP, and octanoylcarnitine (Oct.car) or malate,
ADP, and palmitoylcarnitine (Pal.car). Values are mean±SE. *Different from
WT/Y (P <0.05).
FIGURE 2 | Citrate synthase (CS) enzyme activity (leftY -axis) and
mitochondrial DNA content (rightY -axis) in heart muscle samples
from wild type mice (WT) and dominant negative AMPKα2 (AMPK KD)
mice.Young (Y: 19–22weeks) and old (O: 76–91weeks) mice were studied
in both groups. *Different from age matched wild type (P <0.05).
CARNITINE PALMITOYL TRANSFERASES
There was a high and uniform PCR efﬁciency between the primers
(1.91–1.97, Table 1) and they were thus optimized for the indi-
vidual genes of interest. The levels of β-actin expression showed
no difference between the groups (data not shown) and could
therefore be used as reference-gene. We found a modest down-
regulation of CPT1B expression in old AMPKα2-KD group com-
pared to both old WT and young AMPKα2-KD (Figure 3). We
found no signiﬁcant differences in gene expression of CPT1A and
CPT2.
MYOCARDIAL CONTENT AND ACTIVITY OF METABOLIC KEY ENZYMES
3-Hydroxyacyl-CoA-dehydrogenase protein expression showed
a clear pattern of down-regulation in the AMPKα2-KD in
both age-groups. The expression of HAD was reduced to
FIGURE 3 | Carnitine palmitoyl transferase isoforms 1A (CPT1A) and 1B
(CPT1B) as well as carnitine palmitoyl transferase 2 (CPT2) in heart
muscle samples from wild type mice (WT) and dominant negative
AMPKα2 (AMPK KD) mice.Young (Y: 19–22weeks) and old (O:
76–91weeks) mice were studied in both groups. *Different fromWT/Y
(P <0.05).
FIGURE 4 | 3-Hydroxyacyl-CoA-dehydrogenase (HAD) enzyme activity
(leftY -axis) and protein expression relative toWT/Y (rightY -axis).
*Different fromWT/Y (P <0.05).
0.81± 0.05, P < 0.05 in young AMPKα2-KD compared to WT/Y
and 0.71± 0.04, P < 0.05 in old AMPKα2-KD compared to WT/Y
(Figure 4). Therewas no signiﬁcant age-effect onHADexpression,
indicative of sustained β-oxidative capacity irrespective of old age.
Corresponding with the HAD expression, maximal HAD enzyme
activity was reduced in both AMPKα2-KD age-groups, compared
to their age matched WT littermates (Figure 4).
A considerable decrease in phosphorylated ACCphos was found
in both AMPKα2-KD groups being a consequence of reduced
AMPK activity, in line with previous studies (Dyck et al., 1999;
Zarrinpashneh et al., 2006; Turdi et al., 2010). The expression of
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FIGURE 5 | Protein content (Western blot) of pS212
acetyl-CoA-carboxylase (ACCphos) and malonyl-CoA-decarboxylase
(MCD), glycogen-phosphorylase (GP), hexokinase II (HKII), and
Pyruvatkinase (PKM) in heart muscle samples from wild type mice
(WT) and dominant negative AMPKα2 (AMPK KD) mice.Young (Y:
19–22weeks) and old (O: 76–91weeks) mice were studied in both groups.
Representative blots are shown in the lower panels, which also include
blots of AMPK and AMPKphos. *Different fromWT/Y (P <0.05).
malonyl-CoA-decarboxylase (MCD)was reduced inoldmice, irre-
spective of genotype (P < 0.05, Figure 5). GP was up-regulated in
WT/O compared to WT/Y (1.20± 0.07, P < 0.05, Figure 5). HKII
expression was decreased in both young and old AMPKα2-KD
(P < 0.05, Figure 5) pointing toward a reduced glycolytic capac-
ity in AMPKα2-KD mice independently of age. In contrast, PK
expression was unchanged in both groups of old mice, but sur-
prisingly up-regulated in AMPKα2-KD/Y (Figure 5), indicating
a mixed inﬂuence of age and genotype on the expression of this
enzyme.
DISCUSSION
The major ﬁnding of our study is that loss of AMPKα2 activity
leads to a reduced mitochondrial capacity for oxidative phos-
phorylation when the reducing equivalents are provided via
β-oxidation of MCFA.
We tested this by assessing mitochondrial FA oxidation capac-
ity, both dependently and independently of the mitochondrial
LCFA import apparatus, since palmitoylcarnitine oxidation (pro-
tocol B) requires an intact CPT2, whereas this is not the case
with octanoylcarnitine (protocol A). The selective reduction in
MCFA oxidative capacity within the AMPKα2-KD mice in the
present study coincides with a reduction in HAD enzyme activity
and protein expression in the AMPKα2-KD mice of both age-
groups (Figure 4). This points toward an effect of AMPKα2 in
the regulation of β-oxidation capacity modulated by HAD activ-
ity and expression and is in line with previous studies showing
increased HAD activity and expression in skeletal muscle from
rats treated with 5-aminoimidazole-4-carboxamide (AICAR), a
pharmacologic activator of AMPK (Putman et al., 2003; Fillmore
et al., 2010).
The observed difference between WT and AMPKα2-KD mice
in protein expression and HAD activity (∼20%) was slightly
exceeded by the reduction in MCFA oxidation capacity (∼35–
45%).A linear relationshipmay not necessarily exist between these
variables, but it does leave room for additional factors that may
regulateMCFAoxidation.Mitochondrial FA import could be such
a factor and CPT1 activity has often been referred to as a key
regulator in this respect (Stanley et al., 2005).
The activity of CPT1 is subject to inhibition by malonyl-CoA,
the concentration of which is tightly regulated by ACC and MCD.
In the present study the phosphorylation of ACC showed an obvi-
ous negative effect of the AMPKα2-KD genotype with a 70–74%
reduction of ACCphos in these animals.
The decreased ACCphos levels would in theory lead to inhibi-
tion of LCFA import via CPTI. However we did not observe any
functional difference onLCFAoxidation (protocol B) as palmitoyl-
carnitine oxidation was unaffected by reduced AMPKα2 activity,
arguing against import limitation with this particular FA. It is
important to underline that mitochondrial import of palmitoyl-
carnitine proceeds independently of CPTI and that we were only
able to assess a potentially restricting effect exerted via CPTII in
this experimental model. MCD protein expression shoved a clear
dependence on age with a signiﬁcant reduction in the old mice
of both WT and AMPKα2-KD groups (Figure 5). Low MCD
capacity might lead to increased levels of malonyl-CoA in turn
inhibiting CPTI in old individuals. Together with the reduced
CPT1BmRNAexpression,whichweobserved in the oldAMPKα2-
KD mice (Figure 3), it could be speculated that CPT1 LCFA
import only becomes limiting with advancing age. This could
imply that the capacity of CPT1 is sufﬁcient to meet the LCFA
import requirements of the young, healthy heart – even in the
absence of AMPK stimulation, but that lack of AMPK in the long
term could impose a metabolic challenge upon the myocardium –
leading to a compromised and vulnerable metabolic phenotype in
the old.
Our ﬁnding of selectively reduced MCFA oxidative capacity
in the heart muscle of the AMPKα2-KD mice may be impor-
tant in the pathophysiology of heart failure. In a study in dogs
with heart failure a reduced medium-chain-acyl-dehydrogenase
(MCAD) activity and protein expression was reported (Osorio
et al., 2002), whereas in another study, LCFA oxidative capacity
wasmaintained in dogs with compensated hypertrophy (Chandler
et al., 2004). Decreased palmitoylcarnitine oxidation in isolated
cardiac mitochondria from mice subjected to aortic constriction
was only observed after progression from left ventricular hyper-
trophy to overt heart failure (Faerber et al., 2011). It is therefore
conceivable that a compromised capacity for LCFA oxidation is
a late event in the metabolic remodeling associated with cardiac
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pathology and that the metabolic changes induced by a reduction
of AMPKα2 function may represent an early, disposing factor in
the development of cardiac disease.
Inprevious studies cardiac phenotype,assessedby echocardiog-
raphy, did not differ betweenAMPKα2-KD andWT in youngmice
(Russell III et al., 2004; Turdi et al., 2010) whereas a compromised
LV function was found only in very old AMPKα2-KD mice (aged
24–28months; Turdi et al., 2010) and a more susceptible pheno-
type was demonstrated with respect to acute ischemia (Russell III
et al., 2004). These observations all indicate that a reduced AMPK
activity does not in itself cause cardiac disease, but rather sets the
stage for disease development. With the combined negative effects
of decreased AMPK activity and aging (limited β-oxidative capac-
ity and compromised LCFA import) a future metabolic challenge,
such as acute ischemia, could possibly have negative consequences
for the ATP generating capacity within the cardiac mitochondria
and lead to development of HF.
In general the present data onprotein expression involved in the
glycolytic pathway are somewhat complex. The young AMPKα2-
KD mice exhibited a signiﬁcantly decreased expression of HKII
compared to WT/Y (Figure 5), previously observed in skeletal
muscle of α2-knockoutmice (Jorgensen et al., 2007). The increased
PK protein expression in AMPKα2-KD/Y compared to WT/Y
(Figure 5) is in contrast to the decrease inHKII expression, render-
ing no clear tendency of the glycolytic capacity depending on age
or genotype. The expression of GP was increased in both WT/O
andAMPKα2-KD/Y showing no clear effect of age or genotype on
the extent of glycogen metabolism either.
Some limitations apply to this study. We have not yet been
able to obtain reliable respirometric measurements with LCFA
acyl-CoA as substrate in contrast to LCFA acyl-carnitine. This
prevents us from assessing the functional capacity of CPT1 via the
permeabilized ﬁber technique. Furthermore, echocardiographic
evaluation would have been helpful in the description of aging
and AMPK effects on LV phenotype in the present model. Finally,
the entire data set applies only tomalemice and therefore potential
sex differences cannot be addressed.
In conclusion, we report that loss of AMPK activity is charac-
terized by a selectively reduced MCFA oxidative capacity together
with reduced protein content and enzyme activity of HAD. We
did not ﬁnd any clear effects of aging on the ability to utilize FA as
substrate for mitochondrial respiration.
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